

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number
WO 2004/039833 A1

(51) International Patent Classification⁷: C07K 5/08,
A61K 38/05, 38/06, A61P 31/14

(21) International Application Number:
PCT/CA2003/001634

(22) International Filing Date: 24 October 2003 (24.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/421,900 29 October 2002 (29.10.2002) US
60/442,769 27 January 2003 (27.01.2003) US

(71) Applicant (for all designated States except US):
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LAMARRE, Daniel [CA/CA]; 2100 Cunard Street, Laval, Québec H7S 2G5 (CA). LAGACÉ, Lisette [CA/CA]; 2100 Cunard Street, Laval, Québec H7S 2G5 (CA).


(74) Agent: BERNIER, Louise, G.; Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval, Québec H7S 2G5 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: COMPOSITION FOR THE TREATMENT OF INFECTION BY *FLAVIVIRIDAE* VIRUSES



(57) Abstract: Compositions, use , article of manufacture and method for the treatment of a mammal infected with a virus of the *Flaviviridae* family are provided comprising administration to the infected mammal of a compound having Formula (I), wherein A is selected from: C₁ to C₆ alkyl and C₃ to C₆ cycloalkyl; and B is selected from: phenyl or thiazolyl, both of which optionally substituted with a group selected from NH(R¹) and NH(CO)R¹, wherein R¹ is C₁ to C₆ alkyl; R is OH or a sulfonamide derivative; or a pharmaceutically acceptable salt thereof.





Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**COMPOSITION FOR THE TREATMENT OF INFECTION BY *FLAVIVIRIDAE*
VIRUSES**

FIELD OF THE INVENTION

5 The present invention relates to compounds, compositions, use and method for the treatment of a *Flaviviridae* viral infection in a mammal. More particularly, the present invention relates to the use and a method of treatment comprising administration of a compound selected from a macrocyclic peptide family of compounds.

10 BACKGROUND OF THE INVENTION

The *Flaviviridae* family of viruses are enveloped positive-stranded RNA viruses comprising a number of human pathogenic viruses such as viruses of the hepacivirus genus, including Hepatitis C, viruses of the flavivirus genus, including the Dengue Fever viruses, encephalitis viruses, West Nile viruses and Yellow Fever viruses, and viruses of the pestivirus genus, including the bovine viral diarrhea virus and border disease virus, both of which are animal pathogens. The most newly discovered viruses, hepatitis G virus (HGV) and hepatitis GB virus (GBV-A, B, C), are also provisionally considered to be members of the *Flaviviridae* family belonging to a distinct genus.

20

Dengue viruses, members of the family of *Flaviviridae* are transmitted by mosquitos. There are four serotypes that cause widespread human diseases, one of which causes dengue hemorrhagic fever, and about 40% of the population living in tropical and subtropical regions of the world is at risk for infection. Of the 1 million cases of 25 hemorrhagic fever cases per year, about 5% are fatal. There is currently no effective vaccine or antiviral drug to protect against dengue diseases.

30

Pestiviruses such as bovine diarrhea virus (BVDV), classical swine fever virus (CSFV) and border disease virus (BDV) comprise a group of economically important animal pathogens affecting cattle, pigs and sheep. These positive-sense RNA viruses are classified as a separate genus in the family *Flaviviridae*.

35

GB-viruses have been classified as members of the *Flaviviridae* family, but have not yet been assigned to a particular genus based on the analysis of genomic sequences. These RNA viruses, in addition to infecting humans, can cause acute

resolving hepatitis in experimentally infected tamarins.

Viruses within the *Flaviviridae* family possess a number of similarities despite a relatively low overall sequence homology among its members. The genome of these 5 viruses is a small single-stranded RNA (\approx 10 kilobases in length) having a single open reading frame (ORF). The ORF encodes a polyprotein of about 3000 amino acids that contains structural proteins at its 5' end and non-structural (NS) proteins at its 3' end. The polyprotein is proteolytically processed by both viral and host-encoded proteases into mature polypeptides, which for HCV, are as follows: NH₂-{C-
10 E1-E2-P7-NS2-NS3-NS4A-NS4B-NS5A-NS5B}-COOH. The core protein or nucleocapsid (C) and the two envelope glycoproteins (E1 and E2) represent the constitutive structural proteins of the virions. These structural proteins are followed by the nonstructural (NS) proteins, which at least some are thought to be essential for viral RNA replication.


15 Enzymatic activities have been ascribed to several of these NS proteins. In particular, the NS3 protein contains sequences with similarity to the serine protease and the nucleoside triphosphate-binding helicase of pestiviruses and flaviviruses. Analysis of sequence alignments had predicted the existence of a trypsin-like serine
20 protease domain within the N-terminal region of flavi-, pesti-, hepaci- and GB-viruses. Sequence similarities between NS3 proteolytic domains of *Flaviviridae* viruses are well-established (**Ryan MD et al. 1998**). The HCV NS3 protease domain shares a sequence similarity of about 77-90% among HCV genotypes and a sequence similarity of about 25-50% with other members of the *Flaviviridae* family.
25 With respect to the three dimensional structure, the available atomic co-ordinates of the various crystallized HCV and Dengue NS3 proteases show an overall architecture that is characteristic of the trypsin-like fold (**Kim et al. 1996, Love et al. 1996; Murthy et al. 1999**). Many studies have now firmly established that the N-terminal portion of the NS3 region encodes a serine protease that has a very specific
30 and pivotal role in viral polyprotein processing within *Flaviviridae*. In hepacivirus, pestivirus and GB viruses, polyprotein processing shows a requirement for the downstream NS4A protein. The NS4A protein acts as a cofactor that enhances the NS3 protease cleavage efficiency (**Lin et al., 1995; Kim et al., 1996; Steinkuler et al., 1996**). In flavivirus, this requirement for enhancing the NS3 protease activity is provided by the upstream NS2B protein. The genomic organization and structure of
35

GBV-B and HCV are similar despite the fact that the sequence homology between the polyprotein sequences of GBV-B and HCV is about 25 to 30%.

Given apparent similarities of viruses within the *Flaviviridae* family of viruses, it would
5 be desirable to develop therapeutic agents effective against *Flaviviridae* viruses, and more particularly, effective against the pathogenic members of the *Flaviviridae* family.

SUMMARY OF THE INVENTION

10 Accordingly, in a first aspect of the present invention, there is provided an anti-*Flaviviridae* virus composition comprising a pharmaceutically acceptable carrier in combination with a compound of Formula (I):



15

wherein,

A is selected from: C₁ to C₆ alkyl and C₃ to C₆ cycloalkyl; and **B** is selected from: phenyl or thiazolyl, both of which optionally substituted with a group selected from NH(**R**¹) and NH(CO)**R**¹, wherein **R**¹ is C₁ to C₆ alkyl; **R** is OH or a sulfonamide

20 derivative, or

a pharmaceutically acceptable salt thereof.

In a second aspect, the present invention provides a method for treating a mammal infected with a virus of the *Flaviviridae* family comprising administering to the
25 infected mammal a pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with a therapeutically effective amount of a compound of Formula (I) as defined above.

- In a third aspect, the present invention provides a method of treating a mammal infected with a virus of the *Flaviviridae* family wherein a pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with a
- 5 therapeutically effective amount of a compound of Formula (I) as defined above is co-administered with at least one additional agent selected from: an antiviral agent, an immunomodulatory agent, an HCV inhibitor, an HIV inhibitor, an HAV inhibitor and an HBV inhibitor; to the infected mammal.
- 10 In a fourth aspect, the present invention provides a pharmaceutical composition for treating or preventing an infection of a mammal caused by a virus of the *Flaviviridae* family comprising a pharmaceutically acceptable carrier in combination with a therapeutically effective amount of a compound of Formula (I) and at least one additional agent selected from: an antiviral agent, an immunomodulatory agent, an
- 15 HCV inhibitor, an HIV inhibitor, an HAV inhibitor and an HBV inhibitor.

In a fifth aspect of the present invention, there is provided the use of a compound of Formula (I) as defined above, for the manufacture of a medicament for the treatment of *Flaviviridae* viral infection.

- 20 In a sixth aspect of the present invention, there is provided an article of manufacture comprising packaging material contained within which is a composition effective to inhibit a virus of the *Flaviviridae* family and the packaging material comprises a label which indicates that the composition can be used to treat infection by a virus of the
- 25 *Flaviviridae* family and, wherein said composition comprises a compound of Formula (I) as defined above.

While not wishing to be bound to any particular mode of action, the macrocyclic peptide family of compounds generally represented by Formula (I) as set out above

30 are believed to interact at a conserved substrate binding site in the NS3 protease domain. Crystal structure studies confirm that the present macrocyclic compounds interact at the substrate-binding site within the HCV NS3 domain, a region that is functionally conserved among *Flaviviridae* viruses.

- 35 Other objects, advantages and features of the present invention will become more

apparent upon reading the following non-restrictive description of the preferred embodiments with reference to the accompanying drawings and tables in which:

BRIEF DESCRIPTION OF TABLES

- 5 Tables 4-8 provide a sequence similarity comparison between members of the *Flaviviridae* family.

BRIEF DESCRIPTION OF THE DRAWINGS

- Figure 1 provides a comparison of polyproteins of viruses belonging to the
10 *Flaviviridae* family (taken from: Ryan *et al.*, 1998, J. Gen. Virology 79, 947-959);
Figure 2 is a sequence comparison of the NS3 protease domain between HCV
genotypes and subtypes;
Figures 3A-B are the IC₅₀ curves of a macrocyclic peptide compound according to
Formula (I) against HCV genotype 1a and 1b NS3-NS4A proteases, respectively;
15 Figures 4A-B are the Dixon and Cornish-Bowden plots of the macrocyclic peptide of
Figure 3 against the HCV genotype 1a NS3-NS4A proteases;
Figures 5A-B are the Dixon and Cornish-Bowden plots of the macrocyclic peptide of
Figure 3 against the HCV genotype 1b NS3-NS4A proteases;
Figure 6 illustrates the inhibition of GBV-B replication by macrocyclic peptides
20 according to Formula (I) in tamarin hepatocytes in culture;
Figure 7 graphically illustrates dose-dependent inhibition of GBV-B replication by the
macrocyclic peptide III of Figure 6; and
Figure 8 illustrates the 3-dimensional crystal structure of the HCV NS3-NS4A
peptide structure complexed with a macrocyclic peptide according to Formula (I).
25

DETAILED DESCRIPTION OF THE INVENTION

Definitions

- Unless defined otherwise, the scientific and technological terms and nomenclature
used herein have the same meaning as commonly understood by a person of
30 ordinary skill in the art to which this invention pertains. Generally, the procedures for
cell culture, infection, molecular biology methods and the like are common methods
used in the art. Such standard techniques can be found in reference manuals such
as for example Sambrook *et al.* (1989) and Ausubel *et al.* (1994).

- 35 The term "*Flaviviridae*" as it is used herein to designate a viral family is meant to

encompass viruses of the hepacivirus genus, such as Hepatitis C, viruses of the flavivirus genus, such as the Dengue Fever viruses, Encephalitis viruses, West Nile viruses and Yellow Fever viruses, and viruses of the pestivirus genus, such as the bovine viral diarrhea virus and border disease virus. Hepatitis G virus (HGV) and 5 Hepatitis GB virus are also included in this viral family although the genus of these viruses has not yet been determined. Moreover, all subtypes and genotypes of the above-mentioned viruses are also encompassed within the *Flaviviridae* family, including for example, HCV 1a, HCV1b, HCV 2a-c, HCV 3a-b, HCV 4a, HCV 5 and HCV 6a,h,d & k, as well as GBV-A, B & C.

10

The term "mammal" as it is used herein is meant to encompass humans, as well as non-human mammals which are susceptible to infection by a *Flaviviridae* virus including domestic animals, such as cows, pigs, horses, dogs and cats, and sheep.

15 With respect to the compounds of Formula (I) administered in the treatment of *Flaviviridae* infection, the term "C₁₋₆ alkyl" or "C_{1-C₆}" as used herein, either alone or in combination with another substituent, means acyclic, straight or branched chain alkyl substituents containing from one to six carbon atoms and includes, for example, methyl, ethyl, propyl, isopropyl, butyl, *tert*-butyl, hexyl, 1-methylethyl, 1-methylpropyl, 20 2-methylpropyl, 1,1-dimethylethyl.

The term "C₃₋₆ cycloalkyl" as used herein, either alone or in combination with another substituent, means a cycloalkyl substituent containing from three to six carbon atoms and includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

25

The term "pharmaceutically acceptable salt" means a salt of a compound of formula (I) which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, 30 generally water or oil-soluble or dispersible, and effective for their intended use. The term includes pharmaceutically-acceptable acid addition salts and pharmaceutically-acceptable base addition salts. Lists of suitable salts are found in, e.g., S.M. Birge *et al.* J. Pharm. Sci., 1977, 66, pp. 1-19.

35 The term "pharmaceutically-acceptable acid addition salt" means those salts which

retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoric acid, and the like, and organic acids such as acetic acid, 5 trichloroacetic acid, trifluoroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 2-acetoxybenzoic acid, butyric acid, camphoric acid, camphorsulfonic acid, cinnamic acid, citric acid, digluconic acid, ethanesulfonic acid, glutamic acid, glycolic acid, glycerophosphoric acid, hemisulfic acid, heptanoic acid, hexanoic acid, formic acid, fumaric acid, 2- 10 hydroxyethanesulfonic acid (isethionic acid), lactic acid, maleic acid, hydroxymaleic acid, malic acid, malonic acid, mandelic acid, mesitylenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, nicotinic acid, 2-naphthalenesulfonic acid, oxalic acid, pamoic acid, pectinic acid, phenylacetic acid, 3-phenylpropionic acid, picric acid, pivalic acid, propionic acid, pyruvic acid, pyruvic 15 acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, p-toluenesulfonic acid, undecanoic acid, and the like.

The term "pharmaceutically-acceptable base addition salt" means those salts which retain the biological effectiveness and properties of the free acids and which are not 20 biologically or otherwise undesirable, formed with inorganic bases such as ammonia or hydroxide, carbonate, or bicarbonate of ammonium or a metal cation such as sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically- 25 acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, quaternary amine compounds, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins, such as methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, 30 diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tetramethylammonium compounds, tetraethylammonium 35 compounds, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephedrine,

N,N'-dibenzylethylenediamine, polyamine resins, and the like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

- 5 The term "sulfonamide derivative" as used herein means a sulfonamide group of the formula -NHSO₂-R² wherein R² is -(C₁₋₈)alkyl, -(C₃₋₇)cycloalkyl or {-(C₁₋₆)alkyl-(C₃₋₆)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O-(C₁₋₆)alkyl, amido, amino or phenyl, or R² is C₆ or C₁₀ aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C₁₋₆)alkyl, O-(C₁₋₆)alkyl, amido, 10 amino or phenyl.

The term "antiviral agent" as used herein means an agent (compound or biological) that is effective to inhibit the formation and/or replication of a virus in a mammal. This includes agents that interfere with either host or viral mechanisms necessary for the 15 formation and/or replication of a virus in a mammal. Antiviral agents include, for example, ribavirin, amantadine, VX-497 (merimepodib, Vertex Pharmaceuticals), VX-498 (Vertex Pharmaceuticals), Levovirin, Viramidine, Ceplene (maxamine), XTL-001 and XTL-002 (XTL Biopharmaceuticals).

- 20 The term "immunomodulatory agent" as used herein means those agents (compounds or biologicals) that are effective to enhance or potentiate the immune system response in a mammal. Immunomodulatory agents include, for example, class I interferons (such as α-, β- and omega interferons, tau-interferons, consensus interferons and asialo-interferons), class II interferons (such as γ-interferons) and 25 pegylated interferons.

The term "inhibitor of HCV NS3 protease" as used herein means an agent (compound or biological) that is effective to inhibit the function of HCV NS3 protease in a mammal. Inhibitors of HCV NS3 protease include, for example, those 30 compounds described in WO 99/07733, WO 99/07734, WO 00/09558, WO 00/09543 or WO 00/59929, WO 03/064416; WO 03/064455; WO 03/064456 and the Vertex pre-development candidate identified as VX-950.

- 35 The term "HCV inhibitor" as used herein means an agent (compound or biological) that is effective to inhibit the formation and/or replication of HCV in a mammal. This

includes agents that interfere with either host or HCV viral mechanisms necessary for the formation and/or replication of HCV in a mammal. Inhibitors of HCV include, for example, agents that inhibit a target selected from: NS3 protease, NS3 helicase, HCV polymerase, NS2/3 protease or IRES. Specific examples of inhibitors of HCV 5 include ISIS-14803 (ISIS Pharmaceuticals).

The term "inhibitor of HCV polymerase" as used herein means an agent (compound or biological) that is effective to inhibit the function of an HCV polymerase in a mammal. This includes, for example, inhibitors of HCV NS5B polymerase. Inhibitors 10 of HCV polymerase include non-nucleosides, for example, those compounds described in:

- WO 03/010140 (Boehringer Ingelheim),
 - WO 03/010141 (Boehringer Ingelheim),
 - WO 03/007945 (Boehringer Ingelheim),
 - WO 02/100846 A1 and WO 02/100851 A2 (both Shire),
 - WO 01/85172 A1 and WO 02/098424 A1 (both GSK),
 - WO 00/06529 and WO 02/06246 A1 (both Merck),
 - WO 01/47883 and WO 03/000254 (both Japan Tobacco) and
 - EP 1 256 628 A2 (Agouron).
- 20 Furthermore other inhibitors of HCV polymerase also include nucleoside analogs, for example, those compounds described in:
- WO 01/90121 A2 (Idenix),
 - WO 02/069903 A2 (Biocryst Pharmaceuticals Inc.), and
 - WO 02/057287 A2 and WO 02/057425 A2 (both Merck/Isis).
- 25 Specific examples of inhibitors of an HCV polymerase, include JTK-002/003, JTK-109 (Japan Tobacco), and NM283 (Idenix).

The term "HIV inhibitor" as used herein means an agents (compound or biological) that is effective to inhibit the formation and/or replication of HIV in a mammal. This 30 includes agents that interfere with either host or viral mechanisms necessary for the formation and/or replication of HIV in a mammal. HIV inhibitors include, for example, nucleosidic inhibitors, non-nucleosidic inhibitors, protease inhibitors, fusion inhibitors and integrase inhibitors.

The term "HAV inhibitor" as used herein means an agent (compound or biological) that is effective to inhibit the formation and/or replication of HAV in a mammal. This includes agents that interfere with either host or viral mechanisms necessary for the formation and/or replication of HAV in a mammal. HAV inhibitors include Hepatitis A vaccines, for example, Havrix® (GlaxoSmithKline), VAQTA® (Merck) and Avaxim® (Aventis Pasteur).

- The term "HBV inhibitor" as used herein means an agent (compound or biological) that is effective to inhibit the formation and/or replication of HBV in a mammal. This includes agents that interfere with either host or viral mechanisms necessary for the formation and/or replication of HBV in a mammal. HBV inhibitors include, for example, agents that inhibit HBV viral DNA polymerase or HBV vaccines. Specific examples of HBV inhibitors include Lamivudine (Epivir-HBV®), Adefovir Dipivoxil, Entecavir, FTC (Coviracil®), DAPD (DXG), L-FMAU (Clevudine®), AM365 (Amrad), Ldt (Telbivudine), monoval-LdC (Valtorcitabine), ACH-126,443 (L-Fd4C) (Achillion), MCC478 (Eli Lilly), Racivir (RCV), Fluoro-L and D nucleosides, Robustaflavone, ICN 2001-3 (ICN), Bam 205 (Novelos), XTL-001 (XTL), Imino-Sugars (Nonyl-DNJ) (Synergy), HepBzyme; and immunomodulator products such as: interferon alpha 2b, HE2000 (Hollis-Eden), Theradigm (Epimmune), EHT899 (Enzo Biochem), Thymosin alpha-1 (Zadaxin®), HBV DNA vaccine (PowderJect), HBV DNA vaccine (Jefferson Center), HBV antigen (OraGen), BayHep B® (Bayer), Nabi-HB® (Nabi) and Anti-hepatitis B (Cangene); and HBV vaccine products such as the following: Engerix B, Recombivax HB, GenHevac B, Hepacare, Bio-Hep B, TwinRix, Comvax, Hexavac.
- 25 The term "class I interferon" as used herein means an interferon selected from a group of interferons that all bind to receptor type I. This includes both naturally and synthetically produced class I interferons. Examples of class I interferons include α -, β -, δ -, omega interferons, tau-interferons, consensus interferons, asialo-interferons.
- 30 The term "class II interferon" as used herein means an interferon selected from a group of interferons that all bind to receptor type II. Examples of class II interferons include γ -interferons.

Moreover, the term "therapeutically effective amount" as it is used herein with

respect to compounds of Formula I means an amount of the compound which is effective to treat a *Flaviviridae* viral infection, i.e. to inhibit or at least reduce viral replication, while not being an amount that is toxic to a mammal being treated or an amount that may otherwise cause significant adverse effects in a mammal.


5

The term "carrier" is used to refer to compounds or mixtures of compounds for combination with the present therapeutic compounds which facilitate the administration thereof and/or enhance the function of the therapeutic compounds to inhibit a virus of the *Flaviviridae* family including, for example, diluents, excipients, adjuvants and vehicles. Stabilizers, colorants, flavorants, anti-microbial agents, and the like may also be combined with the therapeutic compound. Moreover, in some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. Other suitable additives include those with which one of skill in the art would be familiar that function to improve the characteristics of the present combination while not adversely affecting its function. Reference may be made to "Remington's Pharmaceutical Sciences", 17th Ed., Mack Publishing Company, Easton, Penn., 1985, for carriers that would be suitable for admixture with the present therapeutic compounds. The term "pharmaceutically acceptable" as it is used herein with respect to a carrier compound is meant to indicate that the carrier is suitable for administration to a mammal, i.e. is non-toxic and does not cause any adverse effect when used in amounts appropriate to function as a carrier.

Preferred Embodiments

25 Anti-*Flaviviridae* virus composition

In a first embodiment of the present invention, there is provided a composition effective to treat a mammal infected with a virus of the *Flaviviridae* family. The composition comprises a pharmaceutically acceptable carrier in combination with a compound of Formula (I):



wherein,

A is selected from: C₁ to C₆ alkyl and C₃ to C₆ cycloalkyl; and **B** is selected from: phenyl or thiazolyl, both of which optionally substituted with a group selected from


- 5 NH(R¹) and NH(CO)R¹, wherein R¹ is C₁ to C₆ alkyl; **R** is OH or a sulfonamide derivative, or a pharmaceutically acceptable salt thereof.

In one embodiment, **A** of Formula (I) is a branched C₄ to C₆ alkyl or C₄ to C₆ cycloalkyl group. In a preferred embodiment, **A** is cyclopentyl or *tert*-butyl.


In another embodiment, **B** of Formula (I) is phenyl or a thiazole substituted at position 2 with NH(R¹) or NH(CO)R¹ in which R¹ is a C₁ to C₄ alkyl. In a preferred embodiment, **B** is a thiazole substituted at position 2 with NH(R¹) or NH(CO)R¹ in which R¹ is a C₁ to C₄ alkyl. More preferably, **B** is 4-thiazole substituted at position 2 with NH(CO)CH₃ or with NHCH(CH₃)₂.

In a further preferred embodiment, **R** of formula (I) is OH or a sulfonamide group of formula -NHSO₂-R² wherein R² is -(C₁₋₆)alkyl, -(C₃₋₆)cycloalkyl, both optionally substituted 1 or 2 times with halo or phenyl, or R² is C₆ aryl optionally substituted from 1 or 2 times with halo or (C₁₋₆)alkyl. More preferably, **R** is OH or a sulfonamide group wherein R² is methyl, cyclopropyl or phenyl.


In a more preferred embodiment, the present invention is conducted with a compound of Formula (I) in which **A** is *tert*-butyl and **B** is phenyl as set out below in the formula of compound (II):



In another more preferred embodiment, the present invention is conducted with a compound of Formula (I) in which **A** is *tert*-butyl and **B** is 4-thiazole substituted at its 2 position with NH(CO)CH₃ as set out below in the formula for compound (III):




In a most preferred embodiment, the present invention is conducted with a compound of Formula (I) in which **A** is cyclopentyl and **B** is 4-thiazole substituted at its 2 position with NHCH(CH₃)₂ as set out below in the formula for compound (IV):




In a most preferred embodiment, the present invention is conducted with a compound of Formula (I) in which **A** is cyclopentyl, **B** is 4-thiazole substituted at its 2

position with $\text{NHCH}(\text{CH}_3)_2$, and **R** is a sulfonamide group wherein R^2 is phenyl as set out below in the formula for compound (VI):




- 5 In a most preferred embodiment, the present invention is conducted with a compound of Formula (I) in which **A** is cyclopentyl, **B** is 4-thiazole substituted at its 2 position with $\text{NHCH}(\text{CH}_3)_2$, and **R** is a sulfonamide group wherein R^2 is methyl as set out below in the formula for compound (VII):



10

In a most preferred embodiment, the present invention is conducted with a compound of Formula (I) in which **A** is cyclopentyl, **B** is 4-thiazole substituted at its 2 position with $\text{NHCH}(\text{CH}_3)_2$, and **R** is a sulfonamide group wherein R^2 is cyclopropyl as set out below in the formula for compound (VIII):



15

Method of Treatment

- In a second aspect of the present invention, a method for treating a mammal infected with a virus of the *Flaviviridae* family is provided comprising administering to an infected mammal a pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with a therapeutically effective amount of a compound having Formula (I), (II), (III), (IV), (VI), (VII) or (VIII) as defined above.
- In accordance with the method of the present invention, a therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (VI), (VII) or (VIII) is administered to a mammal infected with a *Flaviviridae* virus. To be therapeutically effective, a dosage of between about 0.01 and about 100mg/kg body weight per day, preferably between about 0.1 and about 50mg/kg body weight per day of the compound is administered to the infected mammal. Typically, the method will involve administration of the compound from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
- As one of skill in the art will appreciate, lower or higher doses than those recited above may be required. Specific dosage and treatment regimens will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex and diet of the infected mammal, the time of administration, the rate of excretion, the severity and course of the infection, the patient's disposition to the infection and the judgment of the treating physician.
- Generally, treatment is initiated with small dosages substantially less than the optimum dose of the peptide. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. In general, the compound is most desirably administered at a concentration level that will generally afford a therapeutic effect without causing any harmful or deleterious side effects.

Administration of the therapeutic compound in the treatment of *Flaviviridae* viral infection may be by any one of several routes including administration orally, parenterally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-articular,

intrasynovial, intrasternal, intrathecal, and intralesional injection or infusion techniques. Oral administration or administration by injection are preferred. Orally acceptable dosage forms include, but not limited to, capsules, tablets, and aqueous suspensions and solutions.

5

As set out above, the compound of Formula (I), (II), (III), (IV), (VI), (VII) or (VIII) is administered in combination with one or more pharmaceutically acceptable carriers. The nature of the carrier(s) will, of course, vary with the dosage form. Accordingly, in the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added. Injectable preparations including injectable aqueous or oleaginous suspensions, are formulated according to techniques known in the art using suitable dispersing or wetting agents such as Tween 80 and suspending agents.

20 The amount of the present therapeutic compound that is combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% therapeutic compound (w/w). Preferably, such preparations contain from about 20% to about 80% therapeutic compound.

25 In another aspect, a combination therapy is contemplated wherein the compound of Formula (I), (II), (III), (IV), (VI), (VII) or (VIII), or a pharmaceutically acceptable salt thereof, is co-administered with at least one additional agent selected from: an antiviral agent, an immunomodulatory agent, an HCV inhibitor, an HIV inhibitor, an HAV inhibitor, an HBV inhibitor, and a therapeutic effective to treat the symptoms of 30 the viral infection. Examples of such agents are well known to those of skill in the art. These additional agents may be combined with the compounds of this invention to create a single pharmaceutical dosage form. Alternatively these additional agents may be separately administered to the infected patient as part of a multiple dosage form, for example, using a kit. Such additional agents may be administered to the 35 patient prior to, concurrently with, or following the administration of the therapeutic

compound of Formula (I), (II), (III), (IV), (VI), (VII) or (VIII), or a pharmaceutically acceptable salt thereof.

- When a combination therapy is utilized, both the present compound and the
5 additional therapeutic and/or prophylactic agents should be present at dosage levels
of between about 10 to 100%, and more preferably between about 10 and 80% of
the dosage normally administered in a monotherapy regimen.

Article of Manufacture

- 10 In a further aspect of the present invention, there is provided an article of
manufacture comprising packaging material contained within which is a composition
effective to treat a mammal infected with a virus of the *Flaviviridae* family and the
packaging material comprises a label which indicates that the composition can be
used to treat infection by a virus of the *Flaviviridae* family, wherein said composition
15 comprises a compound of Formula (I), (II), (III), (IV), (VI), (VII) or (VIII) as defined
above.

Flaviviridae viruses

- Particularly, the different embodiments of the present invention may be directed to
20 distinct viruses, particularly viruses which are pathogenic in mammal. Preferably, the
above-mentioned compounds of compositions can be used for the treatment of
hepacivirus genus, such as Hepatitis C. Preferred examples of HCV viruses are
selected from genotypes: 1, 2, 3, 4, 5, and 6. More preferred examples of HCV
viruses are selected from genotypes: 2, 3, 4, 5, and 6. Preferably, HCV viruses are
25 selected from subtypes: HCV 1a, HCV1b, HCV 2a-c, HCV 3a-b, HCV 4a, HCV 5 and
HCV 6a,h,d & k. More preferably, HCV viruses are selected from subtypes: HCV 1a,
HCV 2a-c, HCV 3a-b, HCV 4a, HCV 5 and HCV 6a,h,d & k.

- Alternatively, the compounds of the invention may be directed against viruses of the
30 flavivirus genus, such as the Dengue Fever viruses, Japanese Encephalitis viruses,
West Nile viruses and Yellow Fever viruses. Preferably, the invention is directed at
the treatment of viral disease in a human caused by Dengue virus. Preferably, the
invention is directed at the treatment of viral disease in a human caused by
Japanese encephalitis virus. Alternatively, the invention is directed at the treatment
35 of viral disease in a human caused by Yellow Fever virus. Alternatively, the invention

is directed at the treatment of viral disease in a human caused by West Nile virus.

In addition, the invention may be directed to the treatment of viral disease caused by viruses of the pestivirus genus, such as the bovine viral diarrhea virus (BVDV),

5 classical swine fever virus (CSFV) and border disease virus (BDV). Preferably, the invention is directed at the treatment of viral diseases in cattle caused by BVDV.

Alternatively, the invention is directed at the treatment of viral diseases in pigs caused by CSFV. Alternatively, the invention is directed at the treatment of viral diseases in sheep caused by BDV.

10

Furthermore, GB viruses can also be treated with composition of the present invention. Included in this viral family are Hepatitis G virus (HGV) and Hepatitis GB virus. Preferred examples are selected from: GBV-A, B & C. Preferably, the invention is directed at the treatment of viral disease in a human caused by GBV-C.

15 Alternatively, the invention is directed at the treatment of viral disease in a human caused by GBV-A. Alternatively, the invention is directed at the treatment of viral disease in a human caused by HGV.

20 Embodiments of the present invention are exemplified by the following specific examples which are not to be construed as limiting.

EXAMPLES

Abbreviations used in the examples include:

25 Abu: aminobutyric acid; DABCYL: 4-((4-(dimethylamino)phenyl) azo)benzoic acid; DMEM: Dulbecco's Modified Eagle Medium; DMSO: dimethyl sulfoxide; EDANS: 5-((2-aminoethyl)amino)naphthalene-1-sulfonic acid; HPLC: high performance liquid chromatography; IPTG: isopropyl-β-D-thiogalactoside; LB: Luria-Bertoni (as in LB broth); Nva: norvaline; PenStrep: penicillin/streptomycin; PCR: polymerase chain reaction; r.m.s.: root mean square; RT-PCR: real-time polymerase chain reaction; 30 and TCEP: tris(2-carboxyethyl)phosphine hydrochloride.

Synthesis of Compounds of Formula (I)

Compounds of Formula (I) were prepared using the protocol outlined in detail in WO 00/059929, published October 12, 2000. In particular, reference is made to page 89,

35 Example 34C for the preparation of compound (IV).

Example 1 – Inhibition of HCV NS3-NS4A proteases of different genotypes by compounds II, III and IV

HCV NS3/4A 1a and 1b

- 5 For production of the HCV genotype 1b NS3-NS4A heterodimer protein, a full-length HCV cDNA was cloned by RT-PCR using RNA extracted from the serum of an HCV genotype 1b infected individual (provided by Dr. Bernard Willems, Hôpital St-Luc, Montréal, Canada). The DNA region encoding the NS3-NS4A heterodimer protein was PCR-amplified (forward primer: 'CTCGGATCCGGCGCCCATCACGGCCTAC3' (SEQ ID No.1) ; reverse primer: 5'CTCTCTAGATCAGCACTCTTCATTTCATCGAA3') (SEQ ID No.2)) from the full-length HCV cDNA and subcloned into the pFastBacTM HTa baculovirus expression vector (Gibco/BRL). For HCV genotype 1a, the DNA encoding NS3-NS4A heterodimer protein was PCR-amplified (forward primer: 5'CTCTCTAGATCAGCACTCTTCATTTCATCGAACTC3' (SEQ ID No.3); reverse primer: 5'CTCGGATCCGGCGCCCATCACGGCCTACTCCCAA3' (SEQ ID No.4)) from the HCV genotype 1a strain H77 (provided by ViroPharma Inc., Exton, PA, US) and subcloned as described above. The cloning into the pFastBacTM HTa baculovirus expression vector generated a recombinant fusion protein containing an additional N-terminal 28 residues that comprised a hexahistidine tag and a rTEV 10 protease cleavage site. The Bac-to-BacTM baculovirus expression system (Gibco/BRL) was used to produce the recombinant baculovirus for protein expression.
- 15

20 His-tagged NS3-NS4A heterodimer protease was expressed by infecting *Sf21* insect cells (Invitrogen) at a density of 10⁶ cells/mL with the recombinant baculovirus at a multiplicity of infection of 0.1-0.2 at 27°C. The infected culture was harvested 48 to 25 64 h later by centrifugation at 4°C. The cell pellet was homogenized in 50 mM sodium phosphate, pH 7.5, 40% glycerol (w/v), 2mM β-mercaptoethanol. His-NS3-NS4A heterodimer protease was then extracted from the cell lysate with 1.5% NP-30 30 40, 0.5% Triton X-100, 0.5M NaCl, and a DNase treatment. After ultracentrifugation (100,000xg for 30 min at 4°C), the soluble extract was diluted 4-fold in 50 mM sodium phosphate, pH 7.5, 0.5M NaCl and loaded on a Pharmacia Hi-Trap Ni⁺²-chelating column. The His-NS3-NS4A heterodimer protein was eluted using a 50 to 400 mM imidazole gradient prepared in 50 mM sodium phosphate, pH 7.5, 10%

(w/v) glycerol, 0.1% NP-40, 0.5M NaCl. Co-purification of mature NS3 and NS4A protein complex was verified by Western blot analysis of the purified proteins using an anti-NS3 and an anti-NS4A antiserum produced in-house. The purified NS3 protease domain and the peptide H₂N-PDREVLYREFDEMEEC-OH (**SEQ ID No. 5**) were used to immunize rabbits for the production of antisera specific to NS3 and NS4A respectively. The proper N-terminal amino acid of both proteins was confirmed by N-terminal amino acid sequencing (PE Biosystems 491/491C Procise Sequencer). The purified enzymes were stored at -80°C in 50 mM sodium phosphate, pH 7.5, 10% (w/v) glycerol, 0.5 M NaCl, 0.25 M imidazole, 0.1% NP-40.

10

HCV NS3/4A 2b and 3a

The NS3-NS4 protease genes of HCV genotypes 2b and 3a were amplified from RNA isolated from clinical samples of HCV-infected patients obtained from Dr. G. Steinmann (Germany) using RT-PCR. The primers used for the RT- PCR were 5'CTCGGATCCGGCTCCCATTACTGCTTAC3' (**SEQ ID No. 6**) as the forward and 5'GACGCCTCGACGCCGCTCAGCACTCTTCCATTTCACTGAA3' (**SEQ ID No. 7**) as the reverse primer for the NS3-NS4A of HCV genotype 2b and; 5'CTCGGATCGGGCCCCGATCACAGCATACGCC3' (**SEQ ID No. 8**) as the forward and 5'CACCGCTCGAGTCAGCATTCTCCATCTCATATTGTTG3' (**SEQ ID No. 9**) as the reverse primer for HCV genotype 3a . Each primer contained a unique restriction site for subcloning the fragment in the bacterial expression vector pET11a. The cloning into the vector generated a recombinant fusion protein containing an additional N-terminal 28 residues that comprised a hexahistidine tag and a rTEV protease cleavage site. The recombinant plasmids were used to transform the bacterial strain BL21 DE3 pLysS for protein expression and recombinant protein expression was induced by the addition of IPTG. Following expression, the cells were collected by centrifugation at 4°C and the cell pellet lysed in a buffer containing 50mM sodium phosphate, 0.5M NaCl, 40% glycerol, 1.5% NP-40, 0.5% Triton X-100 and the soluble protein fraction was passed through a 5ml HiTrap chelating affinity column as described above. A poly(U)-Sepharose purification step can optionally be conducted in order to remove degradation products and contaminants.

In Vitro HCV NS3 Protease Assay

The fluorogenic depsipeptide substrate used to assess inhibition of protease activity of the HCV 1a, 1b, 2b, 2a-c and 3a NS3-NS4A heterodimer protein was anthranilyl-

DDIVPAbu[C(O)-O]-AMY(3-NO₂)TW-OH (**SEQ ID No.10**). This substrate is cleaved between the aminobutyric (Abu) and the alanine residues. The sequence

DDIVPAbu-AMYTW (**SEQ ID No.11**) is derived from the sequence DDIVPC-

SMSYTW (**SEQ ID No.12**) corresponding to the NS5A/NS5B natural cleavage site.

- 5 The introduction of the aminobutyric residue at position P1 resulted in a significant decrease of the N-terminal product inhibition while the deletion of the serine residue at position P3 improved the internal quenching efficiency. The protease activity was assayed in 50 mM Tris-HCl, pH 8.0, 0.25M sodium citrate, 0.01% n-dodecyl-β-D-maltoside, 1 mM TCEP. The assay was performed in a Microfluor®2 White U-
- 10 Bottom Microtiter® plate. 5 μM of the substrate and various concentrations of the test compound were incubated with 1.5 nM of HCV 1a or 1b NS3-NS4A heterodimer protein for 45 minutes at 23°C under gentle agitation. The final DMSO content did not exceed 5.25%. The reaction was terminated by the addition of a 1M 2-[N-morpholino]ethanesulfonic acid solution at pH 5.8.

15

The fluorescence was monitored using the BMG POLARstar Galaxy 96-well plate reader with an excitation filter of 320 nm, and an emission filter of 405 nm. The level of inhibition (% inhibition) of each well containing test compound was calculated with the following equation (FU = fluorescence unit):

$$20 \quad \% \cdot inhibition = \left(1 - \left[\frac{FU \cdot well - FU \cdot blank}{FU \cdot control - FU \cdot blank} \right] \right) * 100.$$

The calculated % inhibition values were then used to determine IC₅₀, slope factor (n) and maximum inhibition (I_{max}) by the non-linear regression routine NLIN procedure of SAS using the following equation:

$$25 \quad \% \cdot inhibition = \frac{I_{max} \times [inhibitor]^n}{[inhibitor]^n + IC_{50}^n}.$$

Inhibition constant (Ki) determination and mode of inhibition

- The fluorogenic depsipeptide substrate anthranilyl-D(d)EIVP-Nva[C(O)-O] AMY(3-NO₂)TW-OH (**SEQ ID No.13**) was used to assess the mechanism of inhibition and
- 30 the inhibition constants of the compound (**IV**) against HCV NS3-NS4A proteases. It was cleaved between the norvaline and the alanine residues. The substrate working solution was prepared in DMSO at the concentration of 200 μM from the substrate

stock solution (2 mM in DMSO stored at -20°C). The final substrate concentration in the assay varied from 0.25 to 8 µM. The inhibition constant (K_i) for compound (IV) was determined using a steady-state velocity method (Morrisson *et al.* 1985). The protease activity was determined by monitoring the fluorescence change associated
5 with the cleavage of the internally quenched fluorogenic substrate using a SLM-AMINCO® 8100 spectrofluorometer (emission at 325 nm and excitation at 420 nm). The cleavage reaction was monitored in the presence of 0.25 to 8 µM of substrate, 0.3 nM of HCV 1a or 1b NS3-NS4A heterodimer protein and various concentrations
10 of the test compound IV in 50 mM Tris-HCl, pH 8.0, 0.25M sodium citrate, 0.01% n-dodecyl-β-D-maltoside, 1 mM TCEP. The steady-state analysis of inhibition of the HCV genotype 1a and 1b NS3-NS4A heterodimer proteases were performed using the Dixon and Cornish-Bowden graphical methods. In the Dixon graphical method, the reciprocal velocity $1/V$ is plotted against the test compound concentration at several substrate concentrations (S). In the Cornish-Bowden graphical method, the
15 ratio S/V is plotted against the test compound concentration at several S concentrations. For both methods, the points lie on a straight line at each S value. For a competitive test compound, the Dixon plot displays lines at different S values intersecting at a single point, while the Cornish-Bowden plot displays parallel lines at different S values. The K_i was estimated by fitting the data to the equation
20 describing competitive binding:

$$V = \frac{k_{cat} \cdot [E] \cdot [S]}{K_m \cdot (1 + [I]/K_i) + [S]}.$$

Inhibition of HCV NS3 proteases

The activity of HCV genotype 1a, 1b, 2b, 2a-c and 3a NS3/NS4A heterodimer
25 proteases was determined in the presence of compound (IV) using the *in vitro* enzymatic fluorogenic assay. The IC₅₀ curves were analyzed individually by the SAS NLIN procedure. For HCV 1a NS3-NS4A protease, an average IC₅₀ value of 4.3 nM was obtained from the analysis of two batches of compound (IV). An average IC₅₀ value of 3.4 nM was obtained from the analysis of two batches of compound (IV) in
30 the presence of HCV 1b NS3-NS4A protease.

TABLE 1

IC₅₀ of different NS3 protease inhibitors in HCV of different genotypes

compound	HCV-1a	HCV-1b	HCV-3a	HCV-2a-c	HCV-2b
II	7.8 nM	8.9 nM	360 nM	680 nM	1000 nM
III	4.1 nM	4.2 nM	190 nM	490 nM	510 nM
IV	4.3 nM	3.4 nM	280 nM	200 nM	260 nM
V	23 nM	10 nM	930 nM	1800 nM	3000 nM

n/d= not done

Figures 3A and 3B illustrate the IC₅₀ curves of compound (IV) against HCV 1a and

5 1b NS3-NS4A proteases, respectively.

Compound (IV) was found to be a competitive test compound of HCV genotype 1a and 1b NS3-NS4A proteases following fitting of the data to the equation describing competitive binding with GraFit and also from the Dixon and Cornish-Bowden

10 graphical methods. For both HCV genotype enzymes, the Dixon plot showed that the lines at different S values were intersecting at a single point, while the Cornish-Bowden plot showed parallel lines at various S values. A K_i of 0.30 nM was obtained for compound (IV) from steady-state velocity analysis with the HCV genotype 1a NS3-NS4A protease, while a K_i of 0.66 nM was obtained with the HCV genotype 1b NS3-NS4A protease, K_i's of 90 nM, 86 nM and 83 nM with HCV genotype 3a, 2a-c and 2b respectively. Figures 4 and 5 are the Dixon and Cornish-Bowden plots of compound (IV) against the HCV genotype 1a and 1b NS3-NS4A, proteases respectively.

20 **Example 2 – Inhibition of HCV Replicon 1a and/or 1b**

Cell-based HCV 1a and 1b RNA replicon assays

HCV RNA replication was demonstrated in HCV 1a and 1b replicon-containing, Huh-7-derived cell lines developed at Boehringer Ingelheim (Canada) Ltd., R & D (WO 02/052015). These cells were used to establish a sensitive HCV RNA replication cell-based assay for testing candidate test compounds.

Huh7 cells that stably maintain a subgenomic HCV replicon were established as previously described (Lohman *et al.* 1999; WO 02/052015). The cells were seeded

into a 96 well cell culture cluster at 1×10^4 cells per well in DMEM complemented with 10% FBS, PenStrep (Life Technologies) and 1 μ g/mL Geneticin. Cells were incubated in a 5% CO₂ incubator at 37 °C until addition of various concentrations of the test compound.

5

The test compound was prepared for use in the assay as follows. The test compound in 100% DMSO was added diluted in assay Medium for a final DMSO concentration of 0.5% and the solution was sonicated for 15 min and filtered through a 0.22 μ M Millipore Filter Unit. Serial dilutions of the test compounds were prepared 10 using Assay Medium (containing 0.5% DMSO).

Cell culture medium was aspirated from the 96-well plate containing the cells and the appropriate dilution of test compound in assay medium was transferred to independent wells of the cell culture plate which was incubated at 37° with 5% CO₂.

15

Following a 3 day-incubation period, the cells were washed with PBS and total cellular RNA was extracted with the RNeasy Mini Kit® and Qiashredder® from Qiagen. RNA from each well was eluted in 50 μ L of H₂O. RNA was quantified by optical density at 260 nm on the Cary 1E® UV-Visible spectrophotometer. The HCV 20 RNA replicon copy number was evaluated by real-time RT-PCR with the Abi Prism® 7700 Sequence Detection System. The TAQMAN EZ® RT-PCR kit provides a system for the detection and analysis of RNA. Direct detection of the reverse transcription polymerase chain reaction (RT-PCR) product with no downstream processing was accomplished by monitoring the increase in fluorescence of a dye-labeled DNA probe. The nucleotide sequence of both primers and probe was 25 located in the 5' region of the HCV genome. The replicon copy number was then evaluated using a standard curve made with known amounts of replicon copy (supplemented with 50 ng of wild type Huh-7 RNA) assayed in the same reaction mix. The following thermal cycle parameters were used for the RT-PCR reaction on 30 the ABI Prism® 7700 Sequence Detection System. Conditions were optimized for HCV detection. Quantification is based on the threshold cycle, where the amplification plot crosses a defined fluorescence threshold. Comparison of the threshold cycles provides a highly sensitive measure of relative template concentration in different samples. Monitoring during early cycles, when PCR fidelity 35 is at its highest, provides precise data for accurate quantification. The relative

template concentration can be converted to real numbers by using the standard curve of HCV with known number of copy.

EC₅₀ Curve Fitting with NLIN Procedure of SAS

- 5 The level of inhibition (% inhibition) of each well containing test compound was calculated with the following equation (CN = HCV Replicon copy number):

$$\% \cdot \text{inhibition} = \left(\frac{CN \cdot \text{control} - CN \cdot \text{well}}{CN \cdot \text{control}} \right) * 100 .$$

- 10 The calculated % inhibition values were then used to determine EC₅₀, slope factor (n) and maximum inhibition (I_{max}) by the non-linear regression routine NLIN procedure of SAS using the following equation:

$$\% \cdot \text{inhibition} = \frac{I_{\max} \times [\text{inhibitor}]^n}{[\text{inhibitor}]^n + EC_{50}^n} .$$

TABLE 2


- 15 EC₅₀ (nM) of different NS3 protease inhibitors in HCV of different genotypes

compound	HCV replicon 1a	HCV replicon 1b
II	34	27
III	4.5	4.7
IV	2.1	1.0
V	76	39
VI	2.2	3.0
VII	3.2	3.3
VIII	0.7	1.1



- In HCV replicon cell-based assays, compound (IV) showed a dose-dependent inhibition of HCV RNA replication with EC₅₀s of 2.1 nM and 1 nM using HCV replicon-containing cells of genotype 1a and 1b, respectively. Cytotoxicity was not observed at concentrations higher than 1000 nM. These results indicate that compounds II, III, IV, VI, VII and VIII are potent and specific inhibitors of cell-based HCV RNA replication. Compound V is a compound from a different class but which is related in structure, and also active against NS3 protease but less potent. This

compound will be used later on as a control to compare inhibitory activity levels.

Compounds **VI**, **VII** and **VIII** have the following structures:



5



10 **Example 3 – Inhibition of GBV-B NS3/4A protease by compounds II, III and IV**

Cloning of GBV-B NS3/NS4A protease

The full length GBV-B NS3/NS4A protease gene was isolated from infected tamarin serum. Total RNA was isolated from the serum using Qiagen® viral RNA extraction kit according to standard protocol. The selection of primers for the reverse transcriptase and the PCR reactions were selected based on the published sequence (Muerhoff, A.S *et al.* 1995) and GeneBank accession number U22304

(forward: 5'CGCATATGGCACCTTTACGCTGCAGTTC3' (**SEQ ID No.14**);
reverse: 5'CGCGCGCTCGAGACACTCCTCCACGATTCTTC3' (**SEQ ID No.15**)).

The amplified RT-PCR product was cloned into the polyhistidine tag-containing pET-29 plasmid between the NdeI and Xhol sites in frame with the polyhistidine tag. This
5 construct produced a recombinant protein with a poly His tag at its C-terminus. The plasmid was transformed into BL21 DE3 pLysS for protein expression.

The *E. coli* clone pGBV-B was grown in LB medium to a cell density (OD₆₀₀) of 0.6 at which time IPTG was added at a concentration of 0.2 mM. The induction was done
10 at 23°C for a period of 4 hours. The GBV-B NS3/NS4A-His protein was purified according to the procedure described by Zhong *et al.*, 1999. The soluble fraction was purified on a Pharmacia® Hi-Trap Ni²⁺-chelating affinity column using a 50 to 400 mM imidazole gradient. This step was followed by chromatography of the protein preparation on a Superdex® 200 gel filtration column. The concentration of the
15 protein preparation was determined by Bradford protein assay.

In vitro GBV-B NS3 protease assay

The depsipeptide substrate used to assess inhibition of the protease activity of GBV-B NS3-NS4A heterodimer protein was Ac-DED(EDANS)EE-Abu[C(O)-O]
20 ASK(DABCYL)-NH₂ (**SEQ ID No. 16**). This substrate is cleaved between the aminobutyric (Abu) and the alanine residues and products of the reaction were analyzed by HPLC. The protease activity was assayed in 50 mM Tris-HCl, pH 8.0, 0.25M sodium citrate, 0.01% n-dodecyl-β-D-maltoside, 1 mM TCEP. The assay was performed in a Microfluor®2 White U-Bottom Microtiter® plate. 5 μM of the
25 substrate and various concentrations of the test compounds were incubated with 0.4 nM of GBV-B NS3-NS4A heterodimer protein for 2 hours at 23°C under gentle agitation. The final DMSO content did not exceed 5.25%. The reaction was terminated by the addition of a 1M 2-[N-morpholino]ethanesulfonic acid solution at pH 5.8. For quantification, the cleavage products and the substrate were separated
30 by HPLC on a Perkin-Elmer® 3x3CR C8 column. The separation was accomplished by initially eluting at 3.5 mL/min with an aqueous solution containing 0.05% phosphoric acid and 3 mM SDS. A 0 to 45% acetonitrile linear gradient in 0.05% phosphoric acid was then applied for 10 minutes. The absorbance was monitored at 210 nm.

The assay was conducted in the presence of the test compounds **II**, **III**, **IV** and **V**.

The IC₅₀ obtained for each test compound in the presence of GBV-B NS3-4A protein is indicated in Table 3.

TABLE 3

Compounds	IC ₅₀ (μ M) GBV-B
compound (II)	36.5
compound (III)	31
compound (IV)	16
compound (V)	63

5 Compound **V** is a compound from a different class which is related in structure and also active against NS3 protease but less active than compounds **II**, **III** and **IV**. This compound was included to demonstrate that the ranking of the activity of compounds **II**, **III** and **IV** was maintained between HCV and GBV-B.

10 Inhibition of GBV-B replication in tamarin hepatocytes in culture

Hepatocytes isolated from uninfected tamarins were maintained in culture in defined medium for several days. The cell culture model was as described by Beames *et al.* 2000. Three days after plating, the cells were infected with GBV-B-containing plasma. After viral adsorption, the virus was removed and the cells were incubated in 15 the presence and absence of candidate test compounds at a concentration of 10 μ M. The cells were harvested 7 days post infection. The levels of GBV-B RNA were quantitated from total cellular RNA by a real-time PCR assay using a primer-probe combination that recognized a portion of the GBV-B capsid gene (Beames *et al.* 2000).

20

Despite lower IC₅₀ obtained in the enzymatic assay, the results illustrated in Figure 6, show that more than a 3-log reduction in the viral RNA levels was observed when the cells were incubated in the presence of compound **III** and a 2-log reduction in the presence of compound **V** (when the results were expressed as g.e. (genome equivalents)/ μ g RNA). The results obtained with this more representative viral replication assay demonstrate that these compounds are effective antivirals to 25 reduce GBV-B virus production.

Example 4 - Sequence Comparison of NS3 proteases within the *Flaviviridae* family

The sequences of proteases from other viruses of the flaviviridae family of viruses were obtained from a BLAST analysis (Altschul et al. 1997) NCBI followed by the 5 taxonomy report. The search for protease sequences was done using specific criteria that would retrieve all flaviviridae sequences with similarity to HCV protease excluding HCV sequences themselves. When possible an "NP_" sequence from NCBI was used to represent a particular group of related viruses since these "NP_" sequences are "Reference" sequences (RefSeq). Furthermore, when not known, the 10 NS3 N-terminal and C-terminal ends for the proteases were determined from similarity with HCV NS3 protease.

Sequence alignments of proteases for the six HCV strains against the different groups of viruses were performed using ALIGNX (VectorNTI®) based on 15 CLUSTALW (Thompson, JD, et al., 1994).

From these alignments, the percentage of similarity was calculated between all individual sequences and expressed in Tables 4-8. The similarity was based on the following grouping of amino acids; [ILVM], [FWY], [KR], [DE], [GA], [NQ], [ST].

20 Table 4 represents identities and similarities between several genotypes and subtypes of HCV. One can see that identities range between 70% and 89% whereas similarities range between 77% and 95% demonstrating that the NS3 protease is highly conserved among HCV. Also, from the amino acid sequence alignment of 25 NS3 protease domain of various representative HCV genotypes (Figure 2) and location of the conserved residues on the three dimensional structure (Figure 8), one can see that the residues at the active site are highly conserved among HCV genotypes and subtypes.

30 Table 5 is an analysis of the similarity between GB viruses NS3 protease and HCV NS3 protease domains. Similarities range between 43 and 49%, whereas similarities between HCV and pestivirus NS3 domains range from 25 and 30% (Table 6). Similarities between HCV and dengue virus range also around 30% (Table 7), as well as the similarity between HCV and Flavivirus (Table 8).

In contrast, Table 9 shows that the similarities between the NS3 protease domain of HCV and the protease of Human Cytomegalovirus (HCMV) revolves around 20%. HCMV is a virus of the Herpes viridae and has a serine protease that has a different catalytic triad from Flaviviridae proteases. The HCMV virus protease is therefore not 5 considered to be similar to Flaviviridae NS3 proteases. This contrast will be illustrated further when comparison is made of the similarities between the amino acid in contact with our inhibitors in Flaviviridae and HCMV.

Example 5 - Three-Dimensional Structural Crystal Studies

- 10 In order to analyze further the similarities between Flaviviridae, a crystal structure was obtained of the HCV NS3 protease complexed with an inhibitor, and the amino acids directly in contact with the inhibitor were analyzed in other Flaviviridae to assess degrees of similarity of these important contact points.
- 15 A co-crystal of the HCV NS3 protease-NS4A peptide complexed with macrocyclic compound **(II)** was obtained that diffracted X-rays to 2.75 Å resolution. The macrocyclic compound **II** was found at the NS3 protease active site and was clearly defined in the difference electron density. This structure reveals molecular details of how the test compound interacts with the active site and provides additional insight 20 into the mechanism of inhibition of the HCV NS3 protease.

- The structure of the NS3 protease complex with the test compound **II** (Figure 8) better defines the binding site of the present substrate-based test compound series. From this structure of the co-complex, the residues directly in contact with the test 25 compound i.e. within 3 Å (H57, G137, S139, A156 and A157) are indicative of the active site, as predicted by the competitive mode of inhibition, and by the conservation at this site among representative sequences of HCV genotypes and various subtypes.
- 30 Other residues in contact within 4Å of the test compound are listed in Table 10. Comparison analysis reveals that these amino acids are highly conserved among Flaviviridae ranging between 59% and 76%. Conservation of these residues among Flaviviridae is indicative that inhibitors of the HCV NS3 protease would also inhibit other members of the Flaviviridae family of viruses. In contrast, the level of similarity 35 of the HCMV protease catalytic site and the contact points of Table 10 is in the same

range as the similarity for the whole protease (~20%) once again illustrating the fact that other serine protease from non-Flaviviridae are not targeted by the compounds of formula (I).

- 5 Other structural studies performed between HCV and dengue virus protease domains have shown that all six strands of the C-terminal domain inhibitor binding site are strongly conserved and of comparable length. Superposition of 68 α carbon atoms of the C-terminal domain of Den2 protease (residues 87-167) and HCV including most of the residues in Table 10 (residues 69-189) yields a r.m.s. deviation
10 of 0.9 \AA . (Murthy *et al.*, 1999).

Discussion

- Viruses within the *Flaviviridae* family possess a number of similarities (Figure 1) despite a relatively low overall sequence homology among its members (Tables 4-8).
15 In particular, the NS3 protein contains sequences with similarity to the protease and the nucleoside triphosphate-binding helicase of pestiviruses and flaviviruses. The HCV NS3 protease domain shares a sequence similarity of about 77-95% among HCV genotypes (Figure 1) and a sequence similarity of about 25-50% with other members of the *Flaviviridae* family (Tables 4-8). In addition, the genomic
20 organization and structure of GBV-B and HCV are similar despite the fact that the sequence homology between the polyprotein sequences of GBV-B and HCV is about 25 to 30%. This low similarity is however trumped by the fact that residues that come in contact with the inhibitor are highly conserved within the protease domain of Flaviviridae, a strong indication that this family of compounds would also
25 bind to other Flaviviridae. The activity of compound IV obtained against GBV-B is a positive demonstration of that hypothesis.

- With respect to the three dimensional structure, the available atomic co-ordinates of the various crystallized HCV and Dengue NS3 proteases showed an overall
30 architecture that is characteristic of the trypsin-like fold. Many studies have now firmly established that the N-terminal portion of the NS3 region encodes a serine protease that has a very specific and pivotal role in viral polyprotein processing within Flaviviridae.
35 All results produced in the above experiments tend to support the contention that the

compounds of formula (I) are active against members of the Flaviviridae family of viruses:

- 6 related compounds have been shown to be active against HCV 1b and have similar activity against HCV 1a (Table 2);
- 5 • 3 of these compounds were also tested against HCV 3a, 2a-c and 2b and also found to be active (Table 1);
- these 3 same compounds were tested in the enzymatic assay against GBV-B and found to be active (Table 3);
- 10 • 1 of these compounds was tested in cell culture against replication of GBV-B in tamarin cells and found to be active (Figure 6);
- 1 of these compounds demonstrates a mode of binding that is situated in a region highly conserved between all members of Flaviviridae (Figure 8);
- studies have demonstrated strong functional and structural similarity between HCV and Dengue virus NS3 proteases.

15

Given all similarities of viruses within the Flaviviridae family of viruses, it seems highly likely that the compounds of Formula (I) are effective against members of the Flaviviridae family of viruses, and more particularly, effective against the pathogenic members of the *Flaviviridae* family.

20

REFERENCES

- Altschul S.F. et al. 1997, Nucleic Acids Res. 25, 3389-3402
- Ausubel et al. 1994, Current Protocols in Molecular Biology, Wiley, New York
- Beames, B. et al. 2000, J. Virol., 74, 11764-11772
- 25 - Butriewicz, N. et al. 2000, J. Virol., 74, 4291-4301
- Kim JL, et al. 1996, Cell;87:343-355.
- Lin, C. et al. 1995, J. Virol. 69, 4373-4380
- Lohmann et al. 1999, Science 285, 110
- Love R. A. et al. 1996 Cell 87, 331-342
- 30 - Morrison, J.F. and Stone, S.R. 1985, Mol. Cell. Biophys. 2, 347-368
- Muerhoff, A.S. et al. 1995 J. Virol.69, 5621-5630
- Murthy, H. M. et al. 1999, J. Biol. Chem. 274(9), 5573-5580
- Remington, 1995, The Science and Practice of Pharmacy
- Ryan, M. D. et al. 1998 J. Gen. Virol. 79, 947-959
- 35 - Sambrook et al. 1989, Molecular Cloning- A Laboratory Manual, Cold Spring

Harbor Labs

- Scarselli, E., *et al.* 1997, J. Virol. 71, 4985-4989
- Steinkuler, C. *et al.* 1996, J. Biol. Chem. 271, 6367-6373.
- Thompson, *et al.* 1994, Nucleic Acids Res. 22: 4673- 4680
- 5 - Zhong, W. *et al.* 1999, Virology 261, 216-226

TABLE 4 - IDENTITIES AND SIMILARITIES BETWEEN NS3 PROTEASE

	1_1a	1_1b	2_2a	2_2b	3_3a	3_10a	4_4a	5_5a	6_6a	6_11a
1_1a	I = 88% S = 95%	I = 70% S = 81%	I = 71% S = 80%	I = 76% S = 84%	I = 72% S = 82%	I = 81% S = 86%	I = 80% S = 90%	I = 81% S = 88%	I = 88% S = 88%	I = 79% S = 88%
1_1b		I = 71% S = 82%	I = 72% S = 82%	I = 79% S = 87%	I = 76% S = 85%	I = 83% S = 88%	I = 80% S = 91%	I = 82% S = 90%	I = 81% S = 90%	
2_2a			I = 87% S = 95%	I = 74% S = 81%	I = 71% S = 81%	I = 72% S = 82%	I = 71% S = 82%	I = 74% S = 85%	I = 74% S = 86%	
2_2b				I = 70% S = 78%	I = 59% S = 77%	I = 72% S = 81%	I = 71% S = 81%	I = 73% S = 83%	I = 71% S = 83%	
3_3a					I = 89% S = 93%	I = 75% S = 82%	I = 76% S = 83%	I = 79% S = 87%	I = 75% S = 83%	
3_10a						I = 75% S = 82%	I = 76% S = 83%	I = 77% S = 83%	I = 75% S = 82%	
4_4a							I = 79% S = 85%	I = 79% S = 86%	I = 76% S = 85%	
5_5a								I = 82% S = 89%	I = 78% S = 87%	
6_6a									I = 80% S = 88%	

Similarity score was obtained defining the following amino acids similarity:

[IVM], [FWV], [KR], [DE], [GK], [INQ], [ST]

domains (180aa) of the different HCV genotypes and subtypes

TABLE 5 - % SIMILARITY OF HCV NS3 PROTEASE DOMAIN (181 AA) WITH GB NS3

PROTEASES FROM THE FLAVIVIRIDAE FAMILY

	GBV-B NP_056931	HepG NP_043570	GBV-A NP_045010	GBV-C NP_059446
1a AF271632	45	49	44	48
1b D90208	46	49	45	48
2a D00944	44	48	45	47
2b D10988	46	47	45	46
3a D17763	44	45	43	45
10a D63821	43	45	45	46
4a Y11604	44	46	45	45
5a Y13184	46	48	44	46
6a Y12083	45	47	46	46
11a D63822	44	49	45	48

Matrix: [ILVM], [FWY], [KR], [DE], [GA], [NQ], [ST]

TABLE 6 - % SIMILARITY OF HCV NS3 PROTEASE DOMAIN (181 AA) WITH PESTIVIRUSES

NS3 PROTEASES FROM THE FLAVIVIRIDAE FAMILY

	Pesti 1 NP_040937	BVDV2 NP_044731	Pesti 2 NP_075354	Pesti 3 NP_620062
1a AF271632	28	28	28	28
1b D90208	28	28	28	28
2a D00944	26	26	26	26
2b D10988	26	25	26	26
3a D17763	29	28	28	28
10a D63821	28	27	28	28
4a Y11604	28	28	28	28
5a Y13184	29	29	29	29
6a Y12083	30	29	29	29
11a D63822	29	28	29	29

BVDV-2= Bovine viral Diarrhea virus

TABLE 7 - % SIMILARITY OF HCV NS3 PROTEASE DOMAIN (181 AA) WITH MOSQUITO-BORNE FLAVIVIRUS NS3 PROTEASES FROM THE FLAVIVIRIDAE FAMILY

	Dengue 1 NP_059433	Dengue 2 NP_056776	Dengue 3 NP_040961	Dengue 4 NP_073286
1a AF271632	26	27	28	29
1b D90208	29	29	30	31
2a D00944	27	29	28	28
2b D10988	29	29	29	29
3a D17763	27	29	29	29
10a D63821	28	29	30	29
4a Y11604	27	27	28	30
5a Y13184	29	30	31	30
6a Y12083	29	30	30	31
11a D63822	29	29	30	30

TABLE 8 - % SIMILARITY OF HCV NS3 PROTEASE DOMAIN (181 AA) WITH FLAVIVIRUS NS3 PROTEASES FROM THE FLAVIVIRIDAE FAMILY

	WNV NP_041724	JEV NP_059434	Kunjin POLG_KUNJTM	YFV NP_041726	MVEV NP_051124
1a AF271632	29	30	29	29	30
1b D90208	29	31	30	29	31
2a D00944	28	28	28	28	28
2b D10988	29	30	29	30	30
3a D17763	27	27	27	28	28
10a D63821	27	27	27	28	27
4a Y11604	28	29	29	29	30
5a Y13184	29	30	30	30	30
6a Y12083	29	30	30	28	30
11a D63822	28	29	28	29	29

WVN= West Nile virus

JEV= Japanese encephalitis virus

Kunjin= Kunjin virus

YFV= Yellow Fever virus

MVEV= Murray Valley encephalitis virus

TABLE 9 - % SIMILARITY OF HCV PROTEASE DOMAIN (181 AA) WITH HUMAN CYTOMEGALOVIRUS PROTEASE DOMAIN (256 AA)

	HCMV protease
1a AF271632	20
1b D90208	20
2a D00944	21
2b D10988	20
3a D17763	18
10a D63821	18
4a Y11604	19
5a Y13184	19
6a Y12083	19
11a D63822	19

TABLE 10 - AMINO ACID DIFFERENCES IN THE NS3 PROTEASE INHIBITOR BINDING DOMAIN AMONG VIRUSES OF THE (WITHIN 4 Å OF THE INHIBITOR) FLAVIVIRIDAE FAMILY

	HCV40_1b	56 Y	57 H	79 D	81 R	123 V,I	132 L	135 K	136 G	137 S	138 S	139 S	154 F	155 R	156 A	157 A	158 V	168 D	% Sim
HCV																			
All genotypes (140)		E ₂₀	T ₆ K ₁	K/Y +	D +	V/I/M +	F/A +	R/K +	G +	S +	S +	L/F =	V/T =	S/A =	V/A =	L/R =	R +	59	
GBV _a	F/Y +	H +	A/S +	D +	K/Y +	V/I/M +	F/A +	R/K +	G +	S +	S +	L/F =	V/T =	S/A =	V/A =	L/R =	R +	59	
PESTI	D	H	M	D	T	L	K	G	W	S	V	K	V	G	G	G	G	53	
Flavivirus / Mosquito-borne (Dengue)	W	H	K	D	P/N/L +	K/S	P	G	T	S	Y	G	N	G	V	V	A	59	
Flavivirus mosquito-borne	W	H	K	D	P/N/ +	X	G	T	S	Y	G	N	G	N	G	V	A	59	
Herpesvirus HCMV	V	R	V	E	T	G	A	V	D	A	S	V	D	A	L	R	23		

HCV40_1b : Sequence of a HCV 1b isolate that was used as reference for this analysis

n : number of HCV sequences of all genotypes that was used in the study
 A_n : number of HCV sequences containing this modification

% Sim : % similarity

+ : Similarity according to Matrix [ILVM], [FWY], [KR], [DE], [GA], [NQ], [ST]


= : Similarities that are unique for the GBV-B member of the GBV group

GBV_a : The aa in bold are the residue found for GBV-B NS3 protease

_b : % similarity for GBV-B

WE CLAIM:

1. Use of a compound of Formula (I):



Formula (I)

wherein **A** is selected from: C₁ to C₆ alkyl and C₃ to C₆ cycloalkyl; **B** is selected from: phenyl or thiazolyl, both of which optionally substituted with a group selected from NH(R¹) and NH(CO)R¹, wherein R¹ is C₁ to C₆ alkyl; and **R** is OH or a sulfonamide group of the formula -NSO₂-R² wherein R² is -(C₁₋₈)alkyl, -(C₃₋₇)cycloalkyl or {-(C₁₋₆)alkyl-(C₃₋₆)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O-(C₁₋₆)alkyl, amido, amino or phenyl, or R² is C₆ or C₁₀ aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C₁₋₆)alkyl, O-(C₁₋₆)alkyl, amido, amino or phenyl; or a pharmaceutically acceptable salt thereof;

for the preparation of a medicament for the treatment of *Flaviviridae* viral infection in a mammal.

2. The use according to claim 1, wherein **A** of Formula (I) is a branched C₄ to C₆ alkyl or C₄ to C₆ cycloalkyl group; **B** of Formula (I) is phenyl or a thiazole substituted at position 2 with NH(R¹) or NH(CO) R¹ in which R¹ is a C₁ to C₄ alkyl; and **R** is OH or a sulfonamide group of formula -NSO₂-R² wherein R² is -(C₁₋₆)alkyl, -(C₃₋₆)cycloalkyl, both optionally substituted 1 or 2 times with halo or phenyl, or R² is C₆ aryl optionally substituted from 1 or 2 times with halo or (C₁₋₆)alkyl.
3. The use according to claim 1 or 2, wherein **A** is cyclopentyl or *tert*-butyl; **B** is a thiazole substituted at position 2 with NH(R¹) or NH(CO) R¹ in which R¹ is a C₁ to C₄ alkyl; and **R** is OH or a sulfonamide group wherein R² is methyl, cyclopropyl or phenyl.
4. The use according to any one of claims 1 to 3, wherein said compound is a

compound of formula (I) wherein **R** is OH.

5. The use according to any one of claim 1 to 3, wherein **R** is a sulfonamide group of formula -NHSO₂-**R**² wherein **R**² is -(C₁₋₆)alkyl, -(C₃₋₆)cycloalkyl, both optionally substituted 1 or 2 times with halo or phenyl, or **R**² is C₆ aryl optionally substituted from 1 or 2 times with halo or (C₁₋₆)alkyl.
6. The use according to any one of claim 1 to 3, wherein **A** is cyclopentyl; **B** is a thiazole substituted at its 2 position with NHCH(CH₃)₂; and **R** is OH or a sulfonamide group wherein **R**² is methyl, cyclopropyl or phenyl.
7. The use according to any one of claims 1 to 5, wherein said mammal is a human, and said *Flaviviridae* is selected from the group consisting of Yellow Fever virus, West Nile virus, Dengue fever virus, Japanese Encephalitis virus, GB virus A or C and Hepatitis G virus.
8. The use according to any one of claims 1 to 5, wherein said mammal is a cattle, and said *Flaviviridae* is selected from BVDV, border disease virus.
9. The use according to any one of claims 1 to 5, wherein said mammal is a pig, and said *Flaviviridae* is Classical Swine Fever Virus.
10. The use according to claim 5, wherein said mammal is a human, and said *Flaviviridae* is hepatitis C virus.
11. The use according to claim 6, wherein said mammal is a human, and said *Flaviviridae* is selected from the group consisting of Yellow Fever virus, West Nile virus, Dengue fever virus, Japanese Encephalitis virus, GB virus A or C and Hepatitis G virus.
12. The use according to claim 6, wherein said mammal is a cattle, and said *Flaviviridae* is selected from BVDV, border disease virus.
13. The use according to claim 6, wherein said mammal is a pig, and said *Flaviviridae* is Classical Swine Fever Virus.
14. The use according to any one of claims 1 to 9, wherein said *Flaviviridae* virus comprises an NS3 protease comprising amino acid residues selected from: H57, G137, S139, A156 and A157.
15. An article of manufacture comprising packaging material contained within which is a composition effective to inhibit a virus of the *Flaviviridae* family and the packaging material comprises a label which indicates that the composition can be used to treat infection by a virus of the *Flaviviridae* family and, wherein said composition comprises a compound of Formula (I) as defined in claim 1.

FIGURE 1




FIGURE 2

1a	(1)	APITAYAQQTRGLTGTIVTISITGRDKNKNOVGEVQVSTAVQFPLATCINGVWTWVHGAG	61	TRITASPKGPVVIQMYINVDDQIVGWPAPQGSRSITPCICGSSSDLYLVRTHADVIPVRRC	120
1b	(1)	APITAYAQQTRGLTGTIVTISITGRDKNQVDGEVQVSTAVQFPLATCINGVWTWVHGAG	(61)	SKTLAGPKCPITQMYINVDDQIVGWPAPQGARSMHICCGSSSDLYLVRTHADVIPVRRC	
2a	(1)	APITAYAQQTRGLTGTIVTISITGRDKNQAGE1QVLSVQFPLATCINGVWTWVHGAG	(61)	NKTLAGSRCGPVITQMYSSAEGDVGWPSPFGTKSIEQCLCGAVDLYLVRTHADVIPVRRC	
2b	(1)	APITAYAQQTRGLTGTIVTISITGRDKNQAOAGQOMVSSVQFPLATCINGVWTWVHGAG	(61)	NKTLAGPKGPVITQMYSAEGDVGWPSPFGTKSIEQCLCGAVDLYLVRTHADVIPVRRC	
3a	(1)	APITAYAQQTRGLTGTIVTISITGRDKNVVTGEVQVSTAVQFPLATCINGVWTWVHGAG	(61)	SRLAGAKHPALQMYINVDDQIVGWPAPFGKSIEQCLCGESDLYLVRTHADVIPVRRC	
10a	(1)	APITAYAQQTRGLTGTIVTISITGRDKNVVTGEVQVSTAVQFPLATCINGVWTWVHGAG	(61)	SRLTAGAKHPALQMYINVDDQIVGWPAPFGKSIEQCLCGESDLYLVRTHADVIPVRRC	
4a	(1)	APITAYAQQTRGLTGTIVTISITGRDKNVVTGEVQVSTAVQFPLATCINGVWTWVHGAG	(61)	SRITAGAKHPALQMYINVDDQIVGWPAPFGKSIEQCLCGESDLYLVRTHADVIPVRRC	
5a	(1)	APITAYAQQTRGLTGTIVTISITGRDKNVVTGEVQVSTAVQFPLATCINGVWTWVHGAG	(61)	ANTSGPKGPVNOMYINVDDQIVGWPAPPGVRLAYCICGSSDLYLVRTHADVIPVRRC	
6a	(1)	APITAYAQQTRGLTGTIVTISITGRDKNVVTGEVQVSTAVQFPLATCINGVWTWVHGAG	(61)	SKTLAGPKGPVVIQMYINVDDQIVGWPAPPGVRLAYCICGSSDLYLVRTHADVIPVRRC	
11a	(1)	APITAYAQQTRGLTGTIVTISITGRDKNVVTGEVQVSTAVQFPLATCINGVWTWVHGAG	(61)	SKTLAGPKGPVVIQMYINVDDQIVGWPAPPGVRLAYCICGSSDLYLVRTHADVIPVRRC	
Consensus		APITAYAQQTRGLTGTIVTISITGRDKNVVTGEVQVSTAVQFPLATCINGVWTWVHGAG	(61)	SKTLAGPKGPVVIQMYINVDDQIVGWPAPPGVRLAYCICGSSDLYLVRTHADVIPVRRC	
1a	(61)	TRITASPKGPVVIQMYINVDDQIVGWPAPQGSRSITPCICGSSSDLYLVRTHADVIPVRRC	121	DERGELSPRPTISYLKGSSGGPITCPAGGHAVGTERAAVCHRGVAKAVDEFTIPVEVNLTHMR	180
1b	(61)	SKTLAGPKCPITQMYINVDDQIVGWPAPQGARSMHICCGSSSDLYLVRTHADVIPVRRC		DERGELSPRPTISYLKGSSGGPITCPAGGHAVGTERAAVCHRGVAKAVDEFTIPVEVNLTHMR	
2a	(61)	NKTLAGSRCGPVITQMYSSAEGDVGWPSPFGTKSIEQCLCGAVDLYLVRTHADVIPVRRC		DERGELSPRPTISYLKGSSGGPITCPAGGHAVGTERAAVCHRGVAKAVDEFTIPVEVNLTHMR	
2b	(61)	NKTLAGPKGPVITQMYSAEGDVGWPSPFGTKSIEQCLCGAVDLYLVRTHADVIPVRRC		DERGELSPRPTISYLKGSSGGPITCPAGGHAVGTERAAVCHRGVAKAVDEFTIPVEVNLTHMR	
3a	(61)	SRLAGAKHPALQMYINVDDQIVGWPAPFGKSIEQCLCGESDLYLVRTHADVIPVRRC		DERGELSPRPTISYLKGSSGGPITCPAGGHAVGTERAAVCHRGVAKAVDEFTIPVEVNLTHMR	
10a	(61)	SRLTAGAKHPALQMYINVDDQIVGWPAPFGKSIEQCLCGESDLYLVRTHADVIPVRRC		DERGELSPRPTISYLKGSSGGPITCPAGGHAVGTERAAVCHRGVAKAVDEFTIPVEVNLTHMR	
4a	(61)	ANTSGPKGPVNOMYINVDDQIVGWPAPPGVRLAYCICGSSDLYLVRTHADVIPVRRC		DERGELSPRPTISYLKGSSGGPITCPAGGHAVGTERAAVCHRGVAKAVDEFTIPVEVNLTHMR	
5a	(61)	SKTLAGPKGPVVIQMYINVDDQIVGWPAPPGVRLAYCICGSSDLYLVRTHADVIPVRRC		DERGELSPRPTISYLKGSSGGPITCPAGGHAVGTERAAVCHRGVAKAVDEFTIPVEVNLTHMR	
6a	(61)	EKTAGPKGPVVIQMYINVDDQIVGWPAPPGVRLAYCICGSSDLYLVRTHADVIPVRRC		DERGELSPRPTISYLKGSSGGPITCPAGGHAVGTERAAVCHRGVAKAVDEFTIPVEVNLTHMR	
11a	(61)	SKTLAGPKGPVVIQMYINVDDQIVGWPAPPGVRLAYCICGSSDLYLVRTHADVIPVRRC		DERGELSPRPTISYLKGSSGGPITCPAGGHAVGTERAAVCHRGVAKAVDEFTIPVEVNLTHMR	
Consensus		SKTLAGPKGPVVIQMYINVDDQIVGWPAPPGVRLAYCICGSSDLYLVRTHADVIPVRRC	(61)	DISRASLILSPRPISLKGGGGPILCPSSHVGVLFRAAVCTRGVAKALDFIPVESLETTMR	

FIGURE 3

Representative IC₅₀ curves of compound (IV) against HCV genotype 1a (A), and 1b (B) NS3-NS4A proteases



A.**B.**

FIGURE 4

Dixon plot (A) and Cornish-Bowden plot (B) analyses of the inhibition of HCV 1a NS3-NS4A protease by compound (IV) at substrate concentrations of 1 (ν), 2 (ν), 4 (σ) and 6 (λ) μ M showing a competitive mechanism of inhibition.




FIGURE 5

Dixon plot (A) and Cornish-Bowden plot (B) analyses of the inhibition of HCV 1b NS3-NS4A protease by compound (IV) at substrate concentrations of 1 (ν), 2 (ν), 4 (ν) and 6 (μ M showing a competitive mechanism of inhibition.







FIGURE 6**FIGURE 7**

FIGURE 8



SEQUENCE LISTING

5 <110> Boehringer Ingelheim International GmbH
 <120> Composition for the Treatment of Infection by Flaviviridae
 Viruses

10 <130> 13/118
 <140> US 60/442,769
 <141> 2003-01-27

15 <150> US 60/421,900
 <151> 2002-10-29
 <160> 16

20 <170> FastSEQ for Windows Version 4.0

25 <210> 1
 <211> 28
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Primer

30 <400> 1
 ctcggatccg gcgcacatca cggcctac 28

35 <210> 2
 <211> 33
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> primer
 <400> 2
 ctctcttagat cagcactttt ccatttcatac gaa 33

45 <210> 3
 <211> 36
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> primer

50 <400> 3
 ctctcttagat cagcactttt ccatttcatac gaactc 36

```

<210> 4
<211> 34
<212> DNA
<213> Artificial Sequence
5
<220>
<223> primer

<400> 4
10 ctcggatccg gcgcccatca cggcctactc ccaa 34

<210> 5
<211> 16
15 <212> PRT
<213> HCV peptide

<400> 5
Pro Asp Arg Glu Val Leu Tyr Arg Glu Phe Asp Glu Met Glu Glu Cys
20 1 5 10 15

<210> 6
<211> 28
25 <212> DNA
<213> Artificial Sequence

<220>
<223> primer

30 <400> 6
ctcggatccg gctccattta ctgcttac 28

35 <210> 7
<211> 43
<212> DNA
<213> Artificial Sequence

40 <220>
<223> primer

<400> 7
45 gacgcgtcga cgcgccgct cagcactctt ccatttcact gaa 43

<210> 8
<211> 31
<212> DNA
50 <213> Artificial Sequence

<220>
<223> primer

55 <400> 8
ctcggatccg gccccgatca cagcataacgc c 31

```

5 <210> 9
 <211> 41
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> primer

15 <400> 9
 caccgctcg a gtcagcattc ttccatctca tcataattgtt 9 41

20 <210> 10
 <211> 11
 <212> PRT
 <213> Artificial Sequence

25 <220>
 <223> Asp at position 1 is linked to anthranilyl
 <223> Xaa at position 6 is aminobutyric acid [C(O)-O]
 <223> Xaa at position 9 is (3-nitro)tyrosine

30 <400> 10
 Asp Asp Ile Val Pro Xaa Ala Met Xaa Thr Trp
 1 5 10

35 <210> 11
 <211> 11
 <212> PRT
 <213> Artificial Sequence

40 <220>
 <223> Xaa at position 6 is aminobutyric acid

45 <400> 11
 Asp Asp Ile Val Pro Xaa Ala Met Tyr Thr Trp
 1 5 10

50 <210> 12
 <211> 12
 <212> PRT
 <213> HCV Peptide

55 <400> 12
 Asp Asp Ile Val Pro Cys Ser Met Ser Tyr Thr Trp
 1 5 10

5 <210> 13
 <211> 11
 <212> PRT
 <213> Artificial Sequence

10 <220>
 <223> Xaa is at position 1 is anthranilyl-Asp
 <223> Xaa at position 2 is (d)Glu
 <223> Xaa at position 6 is norvaline [C(O)-O]
 <223> Xaa at position 9 is (3-nitro)tyrosine

15 <400> 13
 Xaa Xaa Ile Val Pro Xaa Ala Met Xaa Thr Trp
 5 10

20 <210> 14
 <211> 30
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <223> primer

 <400> 14
 cgcatatggc accttttacg ctgcagtgtc
30
 30

35 <210> 15
 <211> 33
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer

40 <400> 15
 cgcgcgctcg agacactcct ccacgatttc ttc
 33

45 <210> 16
 <211> 9
 <212> PRT
 <213> Artificial Sequence

50 <220>
 <223> Xaa at position 1 is acetylated-Asp
 <223> Xaa at position 3 is Asp (EDANS)
 <223> Xaa at position 6 is amino butyric acid [C(O)-O]
55 <223> Xaa at position 9 is Lys [DABCYL]

60 <400> 16
 Xaa Glu Xaa Glu Glu Xaa Ala Ser Xaa
 1 5

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 03/01634

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07K5/08	A61K38/05	A61K38/06	A61P31/14
-------	----------	-----------	-----------	-----------

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 03 066103 A (BOEHRINGER INGELHEIM PHARMA) 14 August 2003 (2003-08-14) claims 1,33 ---	1-6,10, 14,15
P, X	WO 03 053349 A (SQUIBB BRISTOL MYERS CO) 3 July 2003 (2003-07-03) claims ---	1-6,10, 14,15
P, X	WO 03 064455 A (BOEHRINGER INGELHEIM CA LTD ; GORYS VIDA J (CA); LLINAS-BRUNET MONT) 7 August 2003 (2003-08-07) claims 1,10 ---	1-6,10, 15
X	WO 00 59929 A (BOEHRINGER INGELHEIM CA LTD ; GOUDREAU NATHALIE (CA); GHIRO ELISE () 12 October 2000 (2000-10-12) claims 45,54 ---	1-6,10, 14,15
Y		1-15 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

10 March 2004

Date of mailing of the international search report

29/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beranová, P

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 03/01634

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BÜCHEN-OSMOND, C.: "00.026. Flaviridae" DATABASE UNIVERSAL VIRUS DATABASE , 'Online! 2003, pages 1-3, XP002273068 Columbia University, Oracle, AZ, USA Retrieved from the Internet: <URL:www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/26 000000.htm> 'retrieved on 2004-03-10! -& BÜCHEN-OSMOND, C.: "00.026.0.01. Flavivirus" DATABASE UNIVERSAL VIRUS DATABASE , 'Online! 2003, pages 1-6, XP002274022 Columbia University, Oracle, AZ, USA Retrieved-from-the-Internet: <URL:www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/00 .026.0.01.htm> 'retrieved on 2004-03-10! -& BÜCHEN-OSMOND, C.: "00.026.0.02. Pestivirus" DATABASE UNIVERSAL VIRUS DATABASE , 'Online! 2003, pages 1-4, XP002274023 Columbia University, Oracle, AZ, USA Retrieved from the Internet: <URL:www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/00 .026.0.02.htm> 'retrieved on 2004-03-10! -& BÜCHEN-OSMOND, C.: "00.026.0.03. Hepacivirus" DATABASE UNIVERSAL VIRUS DATABASE , 'Online! 2003, pages 1-4, XP002274024 Columbia University, Oracle, AZ, USA Retrieved from the Internet: <URL:www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/00 .026.03.htm> 'retrieved on 2004-03-10!	1-15
Y		1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 03/01634

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 03066103	A 14-08-2003	WO US	03066103 A1 2003195228 A1	14-08-2003 16-10-2003
WO 03053349	A 03-07-2003	WO US	03053349 A2 2004038872 A1	03-07-2003 26-02-2004
WO 03064455	A 07-08-2003	CA WO US US	2369711 A1 03064455 A2 2003181363 A1 2003224977 A1	30-07-2003 07-08-2003 25-09-2003 04-12-2003
WO 0059929	A 12-10-2000	AU BG BR WO CA CN CZ EE EP HR HU ID JP NO PL SK TR US US	3548000 A 105970 A 0009599 A 0059929 A1 2367127 A1 1346365 T 20013467 A3 200100516 A 1169339 A1 20010720 A1 0300121 A2 30459 A 2002542160 T 20014857 A 350855 A1 14072001 A3 200102878 T2 2004002448 A1 6608027 B1	23-10-2000 31-05-2002 15-01-2002 12-10-2000 12-10-2000 24-04-2002 12-06-2002 16-12-2002 09-01-2002 31-12-2002 28-06-2003 06-12-2001 10-12-2002 31-10-2001 10-02-2003 05-03-2002 21-01-2002 01-01-2004 19-08-2003